Zacks Small Cap Research on MSN20h
RVPH: Year-End OLE Update
RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...
AI-Powered Drug Development Led to This Recent Breakthrough
Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...
BioSpace2d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...